A study of the course and outcome of COVID-19 patients with acute kidney injury admitted in an intensive care unit
DOI:
https://doi.org/10.18203/2349-3933.ijam20221090Keywords:
COVID -19, Acute kidney injury, Intensive care unitAbstract
Background: COVID-19 is a disease which predominantly affects the lung resulting in ARDS and respiratory failure. We described the factors associated with the development of AKI (acute kidney injury) and explored the relation of AKI and mortality in patients with severe COVID-19 admitted in intensive care unit of our hospital.
Methods: A retrospective observational study was conducted in our hospital during the period of April 2021 to June 2021. 182 patients were selected for the study. Ethical committee approval was obtained. Data was analysed using SPSS 20.0
Results: Among the 182 patients, AKI occurred in 99 (54%) patients; 18 (18%) of the patients with AKI required dialysis. The proportions with stages 1, 2, or 3 AKI were 56%, 22% and 21%, respectively. Upon analysis, TC, CRP, D-dimer were significantly higher in patients with AKI compared to non-AKI. Of the 99 patients with AKI, urine studies showed 59% as having proteinuria and 22% having haematuria. Independent predictors of severe AKI were male gender and higher serum potassium at admission. In-hospitalized patients’ mortality was 37% among patients with AKI versus 5% among those without AKI.
Conclusions: AKI complicated the course of nearly 1 in 3 patients hospitalized with COVID-19. Advanced-stage AKI is associated with extremely high mortality among hospitalized COVID-19 patients. Age, male gender, comorbidities which are risk factors for mortality in patients with COVID-19 in the general population are also related to in-hospital mortality in patients with AKI.
References
Infectious disease. Available at: https://www.who.int/ csr/don/05-january-2020-pneumo. Accessed on 20 September 2021.
Coronavirus. Available at: https://www.who.int/emerg encies/diseases/novel-coronavirus-2019/situation-reports/. Accessed on 20 September 2021.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. J Am Med Assoc. 2020;323:1061-9.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-20.
Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospi- tal death of patients with COVID-19. Kidney Int. 2020; 97:829-38.
Hoffmann M, Kleine-Weber H, Krüger N. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. BioRxiv 2020.
Zhao Y, Zhao Z, Wang Y. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019- nCov’. BioRxiv 2020.
Ng JH, Hirsch JS, Hazzan A, Wanchoo R, Shah HH, Malieckal DA, et al. Northwell Nephrology COVID- 19 Research Consortium. Outcomes among patients hospitalized with COVID-19 and acute kidney injury. Am J Kidney Dis. 2021;77(2):204-15.
Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020; 97:829-38.
Nadim MK, Forni LG, Mehta RL, Connor MJ, Liu KD, Ostermann M, et al. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. Nat Rev Nephrol. 2020;16(12):747-64.
Arikan H, Ozturk S, Tokgoz B, Dursun B, Seyahi N, Trabulus S, et al. Characteristics and outcomes of acute kidney injury in hospitalized COVID-19 patients: A multicenter study by the Turkish society of nephrology. PLoS ONE. 2021;16(8):e0256023.
Jewell PD, Bramham K, Galloway J. COVID-19-related acute kidney injury; incidence, risk factors and outcomes in a large UK cohort. BMC Nephrol. 2021; 22:359.
Hamilton P, Hanumapura P, Castelino L, Henney R, Parker K, Kumar M, et al. Characteristics and outcomes of hospitalised patients with acute kidney injury and COVID-19. PLoS One. 2020;15(11): e0241544.
Silver SA, Beaubien-Souligny W, Shah PS. The prevalence of acute kidney injury in patients hospitalized with COVID-19 infection: a systematic review and meta-analysis. Kidney Med. 2021;3(1):83-98e1.
Lian F, Pascual J, Gámez C, Gallego A, Bajo MA, Sicilia LS, et al. Epidemiology of acute renal failure: a prospective, multicenter, community-based study. Kidney Int. 1996;50:811-8.
Mohamed MMB, Lukitsch I, Torres-Ortiz AE. ‘acute kidney injury associated with coronavirus disease 2019 in urban new orleans’. Kidney. 2020;1:614-22.
Cummings MJ, Baldwin MR, Abrams D. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study’. medRxiv 2020;2020.
Zhou F, Yu T, Du R. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study’. Lancet. 2020;395:1054-62.
Tao C, Wu D, Chen H. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091.
Chan L. AKI in hospitalized patients with COVID-19. J Am Soc Nephrol. 2021;32:151-60.
Adamsick ML. Remdesivir in patients with acute or chronic kidney disease and COVID-19. J Am Soc Nephrol. 2020;31:1384-6.
